Oculis Holding AG (OCS) Capital Expenditures (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Capital Expenditures of -$8939.0 for Q1 2026, up 38.18% year-over-year from -$6469.2 in Q1 2025, and up 81.2% quarter-over-quarter from -$47544.5 in Q4 2025.
Analysis
Oculis Holding AG (OCS) Capital Expenditures (2022 - 2026) Analysis & Trends
Oculis Holding AG's Capital Expenditures history runs 5 years deep, the most recent figure standing at -$8939.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 38.18% year-over-year to -$8939.0; the TTM figure through Mar 2026 stood at -$363691.2 (down 38.33% YoY), while the FY2025 annual figure was -$363044.7, down 38.86% from the prior year.
- Capital Expenditures for Q1 2026 stood at -$8939.0, up from -$47544.5 in the prior quarter.
- The five-year high for Capital Expenditures was -$5636.8 in Q4 2023, with the low at -$1.6 million in Q4 2022.
- The 5-year median for Capital Expenditures is -$65066.7 (2024), against an average of -$251973.4.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures surged 99.65% in 2023, then tumbled 1054.33% in 2024.
- Oculis Holding AG's Capital Expenditures stood at -$1.6 million in 2022, then soared by 99.65% to -$5636.8 in 2023, then sank by 1054.33% to -$65066.7 in 2024, then advanced by 26.93% to -$47544.5 in 2025, then jumped by 81.2% to -$8939.0 in 2026.
- Business Quant data shows OCS's Capital Expenditures at -$8939.0 in Q1 2026, -$47544.5 in Q4 2025, and -$155013.6 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | 354,266.95 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 354,266.95 |
| Mar 31, 2026 | 247,738.91 |
| Dec 31, 2025 | 517,984.29 |
| Sep 30, 2025 | -311,277.27 |
| Jun 30, 2025 | 163,065.18 |
| Mar 31, 2025 | 325,889.41 |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | -707,529.04 |
| Jun 30, 2024 | 471,068.03 |
| Mar 31, 2024 | 16,039.55 |
| Dec 31, 2023 | 485,889.78 |
| Sep 30, 2023 | -10,189.37 |
| Dec 31, 2022 | -14,532.31 |
| Sep 30, 2022 | -31,063.70 |